StonvexLoading…
StonvexStonvexStonvexCore line items from PHM's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $3.41B | $17.31B | $12.70B | $8.30B |
Operating Income | Not available | Not available | Not available | Not available |
Net Income | $347.00M | $2.22B | $1.72B | $1.13B |
EPS (Diluted) | $1.79 | $11.12 | $8.55 | $5.60 |
Total Assets | $18.20B | $18.05B | $17.85B | $17.59B |
Total Liabilities | $5.24B | $5.06B | $5.02B | $5.01B |
Cash & Equivalents | $1.81B | $1.98B | $1.45B | $1.23B |
Free Cash Flow OCF − CapEx | $134.35M | $1.75B | $1.01B | $357.60M |
Shares Outstanding | 193.40M | 192.72M | 200.81M | 202.16M |